3D Tissue Models

This person is not registered. Is this you?


Profile Details
Zu-Hang Sheng
Affiliations:

National Institutes of Health

 
Bethesda, MD
Phone: (301) 435-4596
Fax: (301) 480-5763
My Blogs:
My Twitter Hashtags:
@ShengMinZ
 
Age:
Bio:
 
Specialty:
Cancer Immunotherapy
 
Presented at Events Covering:
 
Areas of Interest:
 
Hobbies:
 
General Comments:
BSN Rank: 42212 / 3501 (What's this?)
Accomplish Score: Unavailable
Popularity Score: Unavailable
# in My Circle: 0
# in My Org(s): 802
We'll Post Your CV for Free!
 
 
Speaking/Presenting-Abstract/Poster at Mtg: 0 (0 / 0)
 
Honors and Awards: 0 (0 / 0)
 
Clinical Trial Activity: 0 (0 / 0)
 
Grant Support: 0 (0 / 0)
 
Patents Pending: 0 (0 / 0)
 
Journal - Editor/Reviewer: 0 (0 / 0)
 
Peer Reviewed Papers, Books, Chapters: 3 (18 / 0)
  • PURPOSE: To better understand the efficacy and safety of anti-PD-1/PD-L1 therapy (atezolizumab, pembrolizumab, nivolumab) in patients with previously treated advanced non-small-cell lung cancer (NSCLC). ()
  • Lung cancer is the leading cause of cancer-related death. ()
  • The visualization of the treatment process in situ could facilitate to accurately monitor cancer photothermal therapy (PTT), and dramatically decrease the risk of thermal damage to normal cells and tissues, which represents a major challenge for cancer precision therapy. ()
 
Pre/Non Reviewed Papers, Proceedings: 0 (0 / 0)
 
Membership in Professional Societies: 0 (0 / 0)
 
White Papers: 0 (0 / 0)
 
Registered on BiotechScienceNews: 0

About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.